Tamiya A (2024) Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors. Respir Investig 62:85–89. https://doi.org/10.1016/j.resinv.2023.10.004

Article  CAS  PubMed  Google Scholar 

Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

Article  CAS  PubMed  Google Scholar 

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-X

Article  PubMed  Google Scholar 

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, De Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J (2021) Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer. J. Clin. Oncol 39:723–733. https://doi.org/10.1200/JCO.20.01605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kagohashi K, Miyazaki K, Shiozawa T, Satoh H (2021) Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient. Adv Respir Med 89:316–319. https://doi.org/10.5603/ARM.a2021.0016

Article  PubMed  Google Scholar 

Perdyan A, Sobocki BK, Balihodzic A, Dąbrowska A, Kacperczyk J, Rutkowski J (2023) The effectiveness of cancer immune checkpoint inhibitor retreatment and rechallenge—a systematic review. Cancers 15:3490. https://doi.org/10.3390/cancers15133490

Article  PubMed  PubMed Central  Google Scholar 

Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, Ogata M, Nomura S (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298–32304. https://doi.org/10.18632/oncotarget.25949

Article  PubMed  PubMed Central  Google Scholar 

Hakozaki T, Okuma Y, Kashima J (2018) Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. BMC Cancer 18:302. https://doi.org/10.1186/s12885-018-4212-1

Article  PubMed  PubMed Central  Google Scholar 

Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T (2018) Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol 81:1105–1109. https://doi.org/10.1007/s00280-018-3585-9

Article  CAS  PubMed  Google Scholar 

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot J-M, Ribrag V, Armand J-P, Marabelle A, Soria J-C, Massard C (2018) Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer 101:160–164. https://doi.org/10.1016/j.ejca.2018.06.005

Article  CAS  PubMed  Google Scholar 

Fujita K, Uchida N, Yamamoto Y, Kanai O, Okamura M, Nakatani K, Sawai S, Mio T (2019) Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 39(2019):3917–3921. https://doi.org/10.21873/anticanres.13543

Article  CAS  PubMed  Google Scholar 

Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y, Uchino J, Takayama K (2019) Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med 9:102. https://doi.org/10.3390/jcm9010102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K (2019) The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol 49:762–765. https://doi.org/10.1093/jjco/hyz066

Article  PubMed  Google Scholar 

Gobbini E, Toffart AC, Pérol M, Assié J-B, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Giroux Leprieur E, Vanel F-R, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG (2020) Immune checkpoint inhibitors rechallenge efficacy in non–small-cell lung cancer patients. Clin. Lung Cancer 21(5):e497–e510. https://doi.org/10.1016/j.cllc.2020.04.013

Article  CAS  PubMed  Google Scholar 

Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y (2020) Switching administration of anti-PD -1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review, Thorac. Cancer 11:1927–1933. https://doi.org/10.1111/1759-7714.13483

Article  CAS  Google Scholar 

Hirano S, Hayama N, Tabeta H, Kuroki T, Shiraishi Y, Fujita T, Amano H, Nakamura M, Shimizu S, Nakamura S (2020) Drastic response of rechallenge of nivolumab in a patient with NSCLC who progressed on the first nivolumab treatment. J Thorac Oncol 15:e20–e22. https://doi.org/10.1016/j.jtho.2019.10.012

Article  CAS  PubMed  Google Scholar 

Giaj Levra M, Cotté F-E, Corre R, Calvet C, Gaudin A-F, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assié J-B, Chouaïd C (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer 140:99–106. https://doi.org/10.1016/j.lungcan.2019.12.017

Article  PubMed  Google Scholar 

Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X, Han X, Ma J, Wang L, Tao H, Li X, Zhi X, Huang Z, Hofman P, Prelaj A, Banna GL, Mutti L, Hu Y, Wang J (2020) Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 9(6):2391–2400. https://doi.org/10.21037/tlcr-20-1252

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H (2021) Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902). Lung Cancer 156:12–19. https://doi.org/10.1016/j.lungcan.2021.04.011

Article  CAS  PubMed  Google Scholar 

Xu Z, Hao X, Yang K, Wang Q, Wang J, Lin L, Teng F, Li J, Xing P (2022) Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. J Cancer Res Clin Oncol 148:3081–3089. https://doi.org/10.1007/s00432-021-03901-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T, Nishiki K, Nakase K, Nojiri M, Kato R, Shinomiya S, Fujimoto Y, Oikawa T, Mizuno S (2022) Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer, Thorac. Cancer 13:624–630. https://doi.org/10.1111/1759-7714.14309

Article  Google Scholar 

Xu M, Hao Y, Shi Z, Song Z (2023) Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol 149:17987–17995

Article  CAS  PubMed  Google Scholar 

Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y (2023) Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis, Thorac. Cancer 14:2536–2547. https://doi.org/10.1111/1759-7714.15063

Article  CAS  Google Scholar 

Hu H, Wang K, Jia R, Zeng Z-X, Zhu M, Deng Y-L, Xiong Z-J, Tang J-N, Xie H, Wang Y, Zhang P, Zhou J (2023) Current status in rechallenge of immunotherapy. Int J Biol Sci 19:2428–2442. https://doi.org/10.7150/ijbs.82776

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cybulska-Stopa B, Rogala P, Czarnecka AM, Ługowska I, Teterycz P, Galus Ł, Rajczykowski M, Dawidowska A, Piejko K, Suwiński R, Mackiewicz J, Rutkowski P (2020) Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Adv Med Sci 65:316–323. https://doi.org/10.1016/j.advms.2020.05.005

Article  PubMed